Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:GMANYSE:IAGNASDAQ:SAGANASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMAGeomega ResourcesC$0.18C$0.15C$0.07▼C$0.20C$25.81M1.8885,390 shs19,049 shsIAGIamgold$7.45+0.3%$7.06$3.44▼$8.38$4.28B1.1511.54 million shs9.76 million shsSAGASagaliam Acquisition$10.88$10.88$10.22▼$11.72$591.33M0.01N/AN/ATLXTelix Pharmaceuticals$16.12-2.3%$16.91$13.61▼$30.36$5.46BN/A28,587 shs31,814 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMAGeomega Resources+5.88%+5.88%+28.57%+100.00%+63.64%IAGIamgold+0.13%+1.03%-1.32%+32.21%+95.54%SAGASagaliam Acquisition0.00%0.00%0.00%0.00%0.00%TLXTelix Pharmaceuticals-2.28%-1.68%-4.99%+18.47%+1,612,399,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMAGeomega ResourcesN/AN/AN/AN/AN/AN/AN/AN/AIAGIamgold4.6986 of 5 stars3.43.01.70.03.80.84.4SAGASagaliam AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMAGeomega Resources 0.00N/AN/AN/AIAGIamgold 2.89Moderate Buy$8.2911.28% UpsideSAGASagaliam Acquisition 0.00N/AN/AN/ATLXTelix Pharmaceuticals 3.00Buy$22.3338.51% UpsideCurrent Analyst Ratings BreakdownLatest MPL, IAG, TLX, GMA, and SAGA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.006/30/2025IAGIamgoldRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$8.006/24/2025IAGIamgoldNational BanksharesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/12/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.006/5/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.005/12/2025IAGIamgoldScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$7.50 ➝ $7.755/8/2025IAGIamgoldCIBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperformer ➝ Outperformer$8.40 ➝ $9.204/16/2025IAGIamgoldBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/14/2025IAGIamgoldScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$6.75 ➝ $7.504/4/2025IAGIamgoldRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$8.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMAGeomega ResourcesC$154.21K167.38C$0.04 per share4.12C$0.03 per share6.00IAGIamgold$1.77B2.42$1.00 per share7.44$5.95 per share1.25SAGASagaliam AcquisitionN/AN/AN/AN/A($2.03) per shareN/ATLXTelix Pharmaceuticals$783.21M6.97$0.11 per share144.49$1.12 per share14.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMAGeomega Resources-C$2.02M-C$0.01N/A∞N/AN/A-45.52%-26.01%N/AIAGIamgold$819.60M$1.415.288.100.3845.42%9.26%5.59%8/6/2025 (Estimated)SAGASagaliam Acquisition-$3.41MN/A0.00∞N/AN/A-3.87%-3.30%N/ATLXTelix Pharmaceuticals$32.93MN/A0.0033.59N/AN/AN/AN/AN/ALatest MPL, IAG, TLX, GMA, and SAGA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025IAGIamgold$0.10$0.10N/A$0.07$578.70 million$457.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMAGeomega ResourcesN/AN/AN/AN/AN/AIAGIamgold$0.253.36%N/A17.73%N/ASAGASagaliam AcquisitionN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMAGeomega Resources62.122.176.08IAGIamgold0.291.410.83SAGASagaliam AcquisitionN/A0.130.13TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMAGeomega ResourcesN/AIAGIamgold47.08%SAGASagaliam Acquisition1.40%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipGMAGeomega Resources4.15%IAGIamgold0.17%SAGASagaliam Acquisition0.20%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMAGeomega ResourcesN/A143.40 millionN/ANot OptionableIAGIamgold4,391575.08 million574.11 millionOptionableSAGASagaliam AcquisitionN/A54.35 million54.24 millionNot OptionableTLXTelix PharmaceuticalsN/A338.38 millionN/AN/AMPL, IAG, TLX, GMA, and SAGA HeadlinesRecent News About These CompaniesTelix Pharmaceuticals Stock Short Interest Report | NASDAQ:TLX - BenzingaJuly 3 at 5:30 PM | benzinga.comHC Wainwright & Co. Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Buy RecommendationJuly 3 at 5:30 PM | msn.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What HappenedJuly 3 at 12:48 PM | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Coverage Initiated at HC WainwrightJuly 3 at 8:27 AM | marketbeat.comUp 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'June 30, 2025 | msn.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Still a Buy?June 29, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Here's What HappenedJune 27, 2025 | marketbeat.comTelix Pharmaceuticals Limited: Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial DosesJune 25, 2025 | finanznachrichten.deTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?June 23, 2025 | marketbeat.comIlluccix Approved in U.S. for Patient Selection for Pre-Taxane RLTJune 23, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?June 20, 2025 | marketbeat.comTelix Precision Medicine Announces AlFluor Radiochemistry PlatformJune 20, 2025 | globenewswire.comTelix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025June 19, 2025 | globenewswire.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Stock Price Down 6.7% - Time to Sell?June 13, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Time to Buy?June 12, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares' (TLX) "Outperform" Rating Reaffirmed at WedbushJune 12, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Time to Sell?June 6, 2025 | marketbeat.comWilliam Blair Has Positive Estimate for TLX FY2025 EarningsJune 6, 2025 | marketbeat.comWedbush Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Outperform RecommendationJune 5, 2025 | msn.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Here's WhyJune 5, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Now Covered by WedbushJune 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAMD Accelerates Stack Development: Share Price to FollowBy Thomas Hughes | June 16, 2025View AMD Accelerates Stack Development: Share Price to FollowAre NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista?By Leo Miller | June 6, 2025View Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista?Update! What Is Congress Trading So Far In 2025? By Thomas Hughes | June 5, 2025View Update! What Is Congress Trading So Far In 2025? FedEx Stock Is at Its Bottom—And It May Be Time to BuyBy Thomas Hughes | June 26, 2025View FedEx Stock Is at Its Bottom—And It May Be Time to BuyDave & Buster’s: Short-Covering Rally Signals Big Upside for PLAYBy Thomas Hughes | June 11, 2025View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAYMPL, IAG, TLX, GMA, and SAGA Company DescriptionsGeomega Resources CVE:GMAC$0.18 0.00 (0.00%) As of 03:31 PM EasternGeomega Resources Inc. engages in the acquisition, evaluation, and exploration of mining properties in Canada. The company primarily explores for rare earth elements and niobium deposits. It owns a 100% interest in the Montviel property comprising 106 mining claims covering an area of approximately 5,889 hectares located 100 km north of Lebel-surQuévillon and 45 km west of the Cree First Nation of Waswanipi. The company was incorporated in 2008 and is headquartered in Boucherville, Canada.Iamgold NYSE:IAG$7.45 +0.02 (+0.27%) Closing price 07/3/2025 03:50 PM EasternExtended Trading$7.45 0.00 (0.00%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IAMGOLD Corporation, through its subsidiaries, operates as an intermediate gold producer and developer in Canada and Burkina Faso. It owns 100% interest in the Westwood project that covers an area of 1,925 hectare and located in Quebec; a 60% interest in the Côté gold project, which covers an area of 596 square kilometer located in Ontario, Canada; and a 90% interests in the Essakane project that covers an area of 274,000 square kilometer situated in Burkina Faso. IAMGOLD Corporation was incorporated in 1990 and is headquartered in Toronto, Canada.Sagaliam Acquisition NASDAQ:SAGASagaliam Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify target business in the telecommunications, media, and technology industries. Sagaliam Acquisition Corp. was incorporated in 2021 and is based in Los Angeles, California.Telix Pharmaceuticals NASDAQ:TLX$16.12 -0.38 (-2.28%) As of 07/3/2025 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
